LARIMAR THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
LARIMAR THERAPEUTICS INC. - More news...
LARIMAR THERAPEUTICS INC. - More news...
- Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
- Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
- Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
- Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
- Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
- Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
- Larimar Therapeutics Announces Proposed Underwritten Public Offering
- Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
- Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
- Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
- Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
- Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
- Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
- Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
- Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
- Larimar Therapeutics Set to Join Russell 3000® Index
- Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
- Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
- Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
- Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
- Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
- Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
- Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
- Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
- Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
- Larimar Therapeutics Announces $70 Million Underwritten Offering
- Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients